

1

2 Effect of diabetic kidney disease complications on fatigability in patients with type 2 diabetes mellitus

3

4 Short title: Effect of DKD complication in T2DM

5

6 Yuma Hirano,^{1,*} Daisuke Tsuruya,² Kenichi Kono,³ Tomoyuki Fujikura,⁴ Tomoya Yamaguchi,¹ Kento

7 Matsushita,¹ Yurina Yokoyama,¹ Katsuya Yamauchi,¹ Yusuke Nishida³

8

9 ¹Department of Rehabilitation Medicine, Hamamatsu University Hospital, Hamamatsu city, Shizuoka,

10 Japan

11 ²Internal Medicine 2, Hamamatsu University Hospital, Hamamatsu city, Shizuoka, Japan

12 ³Department of Physical Therapy, International University of Health and Welfare School of Health

13 Science at Narita, Narita city, Chiba, Japan

14 ⁴Internal Medicine 1, Division of Nephrology, Hamamatsu University School of Medicine, Hamamatsu

15 city, Shizuoka, Japan

16

17 ***Corresponding author:**

18 E-mail: yuma.h.pt@gmail.com (YH)

19 ORCID: Yuma Hirano (0000-0002-3310-5701)

20

21

22

23

24

25

26

27

28

29

30 Abstract

31 **Purpose:** Type 2 diabetes mellitus (T2DM) emphasizes the maintenance of high levels of physical
32 activity and requires interventions tailored to the characteristics of each patient. We hypothesized that
33 T2DM combined with diabetic kidney disease (DKD) could increase skeletal muscle fatigability,
34 becoming a specific contributor to physical inactivity. This study aimed to determine the effects of DKD
35 complications on fatigability and the relationship between fatigability and physical activity in patients
36 with T2DM.

37 **Methods:** The participants were 50 patients with T2DM aged 40–65 years with an estimated
38 glomerular filtration rate of 30 ml/min/1.73 m² or higher. An experimental protocol was performed using
39 a isokinetic dynamometer to assess muscle function. Fatigability (maximal voluntary concentric
40 contraction [Δ MVCC] velocity, maximal voluntary isometric contraction [Δ MVIC] torque) was
41 calculated, indicating the decrease in angular velocity and muscle strength associated with the exercise
42 task. The patient characteristics, physical activity (IPAQ-SV), knee extension strength, and skeletal
43 muscle index were evaluated. Participants were divided into two groups (DKD and non-DKD) according
44 to the presence or absence of DKD, and Δ MVCC velocity and Δ MVIC torque were compared.

45 **Results:** Δ MVCC velocity was significantly higher in the DKD group than that in the non-DKD
46 group ($p < 0.05$). Similarly, Δ MVIC torque was significantly higher in the DKD group compared with the
47 non-DKD group ($p < 0.05$). Subgroup analysis showed that Δ MVCC velocity was independently
48 associated with physical activity in the DKD group (odds ratio: 0.045, 95% confidence interval:
49 0.913–0.999).

50 **Conclusion:** Fatigability increased with DKD in patients with T2DM and may be related to
51 physical activity.

52

53

54 Introduction

55 Type 2 diabetes mellitus (T2DM) is an important chronic disease characterized by chronically elevated
56 blood glucose levels. Maintaining a high level of physical activity is crucial for controlling blood glucose
57 levels and preventing complications. Understanding the mechanism of reduced physical activity in
58 patients with T2DM, with its diverse pathological conditions due to complications, poses a challenge.
59 Therefore, clarifying the mechanism of reduced physical activity specific to each patient's complications
60 is essential. In this study, we focused on elucidating the factors associated with the amount of physical
61 activity in patients with T2DM and renal dysfunction, specifically those with diabetic kidney disease
62 (DKD). DKD accounts for >40% of the underlying diseases in patients undergoing dialysis in Japan,
63 emphasizing a significant need for intervention.

64 T2DM is commonly associated with several musculoskeletal disorders [1] that pose significant barriers
65 to regular exercise and physical activity [2,3]. Musculoskeletal disorders involve decreased muscle
66 strength and power and increased muscle fatigability [4]. In contrast to chronic fatigue, fatigability is
67 conceptualized as a symptom associated with physical activity and defined as a reversible, short-term,
68 activity-related decrease in muscle strength, power, or speed [5]. Fatigue symptoms may be chronic,
69 whereas fatigability is reversible with rest [6]. Fatigability is associated with decreased exercise tolerance
70 and adherence [7]. Additionally, the ability to perform repetitive or prolonged daily physical activities,
71 particularly walking, climbing stairs, and carrying loads, is limited by fatigability [8].

72 Previous reports have shown that patients with prediabetes and T2DM had greater fatigability than did
73 healthy individuals [4,9,10]. Fatigability is associated with skeletal muscle atrophy, mitochondrial
74 dysfunction, decreased hemoglobin concentration, and decreased muscle blood flow [11]. Among these,
75 skeletal muscle atrophy and reduced muscle blood flow are consistent with the characteristics of patients
76 with chronic kidney disease (CKD), including mild cases [12-15]. Therefore, fatigability in T2DM may
77 increase with DKD, potentially hindering physical activity.

78 However, few studies have examined the effects of DKD on fatigability in patients with T2DM.
79 Additionally, none have examined the relationship between fatigability and physical activity. Therefore,
80 we hypothesized that T2DM combined with DKD would be associated with greater fatigability and
81 reduced physical activity compared with T2DM alone. In this study, we compared fatigability in patients

82 with T2DM and DKD and evaluated the effects of comorbid DKD on fatigability. We also assessed the
83 relationship between fatigability and physical activity, aiming to identify factors associated with physical
84 activity levels in patients with DKD and inform the planning of personalized exercise programs.

85

86 **Material and methods**

87 **Study design, setting, participants, and addressing bias**

88 This was a single-center, cross-sectional study of patients with T2DM who visited outpatient clinics
89 between April 2020 and March 2023. The inclusion criteria were: (a) age between 40 and 65 years, (b)
90 ambulatory independence, and (c) estimated glomerular filtration rate (e-GFR) of 30 ml/min/m² or higher.
91 The exclusion criteria were: (a) inability to provide consent to participate in the study, (b) coexisting
92 severe cardiac or pulmonary disease, and (c) inability to complete the study protocol due to orthopedic or
93 psychiatric diseases. The ultimate goal of this study was to prevent poor glycemic control and progression
94 of renal complications due to physical activity restriction. Therefore, focusing on patients with early DKD
95 was necessary; we enrolled patients with e-GFR ≥ 30 mL/min/1.73 m². Furthermore, a significant
96 difference in fatigability between younger and older patients has been reported [16]. Therefore, to
97 minimize the influence of age, only patients aged 40–65 years were included in this study. Written
98 informed consent was obtained from all participants before they participated in the study. The study was
99 approved by the Clinical Research Ethics Committee of the Hamamatsu University School of Medicine
100 (20-002). This cross-sectional study followed the Strengthening the Reporting of Observational Studies in
101 Epidemiology guidelines for reporting cross-sectional studies.

102 **Outcomes**

103 Our main outcomes were fatigability and physical activity.

104 Fatigability was assessed by an experimental protocol using an isokinetic dynamometer for muscle
105 function assessment (SAKAImed, BIODEX System3), according to previous studies [16] (Fig 1). The
106 experimental protocol consisted of baseline and dynamic fatiguing tasks (DFT). The participants were
107 seated on an isokinetic dynamometer for muscle function assessment, with their hip joints flexed at 90°
108 and their shoulders, hips, and ankles immobilized. The exercises performed in this study included

109 maximal voluntary concentric contractions (MVCC) and maximal voluntary isometric contractions
110 (MVIC) during knee extension. Measurements were taken regarding angular velocity (deg/s) for the
111 MVCC and torque (Nm) for the MVIC. The participants were verbally instructed to use maximum
112 velocity in all MVCCs and maximum force in all MVICs. During each cycle in the MVCC, the
113 participants performed knee extension by contracting the muscles as fast as possible in a 90° range of
114 motion. After the contraction was complete, the muscles were relaxed and passively returned to the
115 starting position by the machine. The experimental protocol was performed by three individuals, one
116 physician, and two physiotherapists trained in measurement. At baseline, the participants performed three
117 MVICs with a rest between each trial. Fifteen MVCC cycles were performed at a load of 20% of the
118 maximum torque value measured by the MVIC. At each MVIC, maximal muscle force was exerted for 5 s.
119 The DFT consisted of 30 consecutive MVCCs once every 3 s, followed immediately by the MVIC. This
120 was considered a set, and three sets were performed consecutively. The maximum value of the three
121 MVICs measured in the baseline task was taken as the base MVIC, and the average value of the fastest
122 five consecutive times of the 15 MVCCs was taken as the base MVCC. Additionally, for each set of
123 MVCCs in the DFT, the average value (v1 to v3) of the last 5 out of 30 contractions was calculated. From
124 base MVCC and base MVIC, the rate of decrease in the third set of MVCC and MVIC in DFT was
125 quantified as Δ MVCC velocity and Δ MVIC torque, respectively, and this was defined as fatigability.

126

127 **Fig 1** Experimental protocol for the assessment of fatigability

128 Fatigability was assessed by performing an experimental protocol using an isokinetic dynamometer to
129 assess muscle function. The exercises performed in this study included maximal voluntary concentric
130 contractions (MVCC) and maximal voluntary isometric contractions (MVIC) during knee extension. The
131 black and gray bars represented MVIC and MVCC, respectively. At baseline, the participants performed
132 three MVICs. Subsequently, they performed 15 MVCCs at a load of 20% of the maximum torque value
133 measured by the MVIC. The dynamic fatiguing task consisted of 30 consecutive MVCC cycles, one every
134 3 s, followed by MVIC (t1~t3) performed immediately after each MVCC cycle. This was performed in
135 one set and continued for three sets.

136

137 Physical activity was assessed using the Japanese Short Version of the International Physical Activity

138 Questionnaire (IPAQ). The questionnaire assessed the amount of physical activity in each category (high
139 intensity, moderate intensity, and walking) over 7 days. Metabolic equivalents (METs) of 8.0, 4.0, and 3.3
140 were assigned to vigorous-intensity physical activity, moderate-intensity physical activity, and walking,
141 respectively, according to official IPAQ guidelines [17]. The METs were multiplied by the activity time of
142 each item and the number of performance days per week, and the amount of physical activity for each
143 item and its total value were calculated as the amount of physical activity (METs min/week). Moreover,
144 the participants were divided into three groups according to the official IPAQ guidelines: low physical
145 activity (<600 METs min/week), moderate physical activity (600–2999 METs min/week), and high
146 physical activity (>3000 METs min/week).

147 **Exposures**

148 The primary exposure variable was the presence or absence of DKD. The participants were divided into
149 DKD and non-DKD groups based on the presence or absence of DKD. DKD was defined as albuminuria
150 ≥ 30 mg/gCr or renal dysfunction without albuminuria (eGFR <60 ml/min/1.73 m²). The eGFR was
151 calculated according to the Japanese estimation formula using serum creatinine concentration [18].

152 **Potential modifiers**

153 Knee extension strength and skeletal muscle mass index (SMI) were assessed as potential confounders of
154 fatigability and physical activity levels. Knee extension strength and skeletal muscle mass are known
155 functions of the musculoskeletal system. Reports suggest their tendency to decrease with renal
156 impairment and may be related to fatigue [11]. Additionally, they are associated with the amount of daily
157 physical activity in patients with CKD [19]. For knee extension strength, we used the maximum of the
158 three MVICs measured at the baseline of the experimental protocol divided by body weight. Skeletal
159 muscle index was assessed using a body composition analyzer (InBody Japan, InBody 270). The
160 participants stood at the machine after entering personal information such as height, age, and sex. The
161 participants were assessed in a static standing position.

162 **Covariates**

163 The other variables of interest included age and sex as demographic characteristics. Fatigability increases
164 with age [16, 20], and men are more likely to have increased fatigability than women [21].

165 **Statistical analysis**

166 The participant characteristics are reported as mean (standard deviation [SD]) or median (interquartile
167 range [IQR]) for continuous variables and as counts and proportions for categorical variables. Inferential
168 statistical analyses using t-tests, chi-square, and Mann-Whitney U tests were performed to compare the
169 characteristics of clinical disease information, patient demographics, fatigability, knee extension strength,
170 and SMI between patients with and without kidney disease. Comparisons of fatigability between patients
171 with and without kidney disease were performed using analysis of covariance, including age, sex, knee
172 extensor strength, and SMI as adjustment variables. Moreover, ordinal logistic regression analysis
173 examined the association between physical activity and fatigability in all participants, including subgroup
174 analysis for the DKD and non-DKD groups. Independent variables included fatigability, age, sex, knee
175 extensor strength, and SMI. Statistical significance was set at $p < 0.05$. IBM SPSS version 26 was used
176 for data analysis.

177

178 **Results**

179 **Participant characteristics**

180 Of the 73 patients who met the selection criteria, 50 were included in the analysis, and 23 were excluded.
181 After classification, 31 and 19 patients were assigned to the DKD and non-DKD groups, respectively (Fig
182 2). All 50 participants had complete data for analysis. The participants had a median age of 54.5 (IQR,
183 48.3–61.8) years, a mean BMI of 27.5 ± 5.3 kg/m², and 52.0% were male individuals. Among the
184 participants, 56.0% had hypertension, 68.0% had dyslipidemia, and 20.0% had coexisting cardiovascular
185 disease (Table 1).

186

187 **Table 1 Characteristics of the study participants**

	All (N = 50)	DKD group (n = 31)	Non-DKD group (n = 19)	<i>p</i> -Value
Age (years)	54.5 (48.3–61.8)	57.0 (50.0–62.0)	51.0 (48.0–59.5)	0.347

Male [N, (%)]	26 (52.0)	15 (48.4)	11 (57.9)	0.514
BMI (kg/m ²)	27.5 ± 5.3	27.1 ± 5.4	28.6 ± 5.0	0.491
Current smoking [N, (%)]	9 (18.0)	4 (12.9)	5 (26.3)	0.205
Diabetic retinopathy [N, (%)]	8 (16.0)	7 (22.6)	1 (5.3)	0.108
Hypertension [N, (%)]	28 (56.0)	18 (58.1)	10 (52.6)	0.707
Hyperlipemia [N, (%)]	34 (68.0)	20 (64.5)	14 (73.7)	0.500
Cardiovascular diseases [N, (%)]	10 (20.0)	5 (16.1)	5 (26.3)	0.301
HbA1c (%)	7.6 (7.1–8.2)	7.6 (7.1–8.2)	7.5 (7.0–8.1)	0.719
Hemoglobin (g/dl)	14.7 ± 1.9	14.4 ± 2.1	15.2 ± 1.4	0.133
Creatinine (mg/dl)	0.82 ± 0.26	0.85 ± 0.28	0.78 ± 0.22	0.408
e-GFR (ml/min/1.73 m ²)	73.8 ± 3.0	71.0 ± 22.7	78.2 ± 17.8	0.246
Knee extension strength (Nm/kg)	1.8 (1.5–2.5)	1.7 (1.5–2.0)	2.3 (1.2–2.8)	0.285
Skeletal muscle index (kg/m ²)	7.6 ± 1.2	7.5 ± 1.2	7.7 ± 1.2	0.526
Fatigability				
ΔMVCC velocity (%)	35.9 ± 17.0	39.8 ± 17.4	29.5 ± 14.6	0.036 [#]
ΔMVIC torque (%)	26.7 ± 15.6	29.8 ± 14.3	21.5 ± 16.5	0.067
Physical activity				
Low [N, (%)]	9 (18.0)	9 (29.0)	0 (0.0)	
Moderate [N, (%)]	26 (52.0)	15 (48.4)	11 (57.9)	0.027 [#]
High [N, (%)]	15 (30.0)	7 (22.6)	8 (42.1)	

188 Data are expressed as numbers (percentages) or mean ± standard deviation or median (interquartile
189 range).

190 The p-value indicates a significant difference between the DKD group and the non-DKD group using
191 unpaired t test, Mann–Whitney U test, χ^2 test, or Fisher’s exact test.

192 *BMI* body mass index, *HbA1c* hemoglobin A1c, *e-GFR* estimated glomerular filtration rate, *MVCC*
193 maximal voluntary concentric contractions, *MVIC* maximal voluntary isometric contractions.

194 [#]p < 0.05

195

196 **Fig 2** Selection of participants for analysis and assignment to the two groups

197 Of the 73 patients who met the selection criteria, 50 were included in the final analysis, and 23 were
198 excluded. After classification, 31 and 19 patients were assigned to DKD and non-DKD groups,
199 respectively. *DKD* diabetic kidney disease.

200

201 **Kidney disease**

202 Of the participants in this study, 31 (62%) had concomitant DKD, and the demographic characteristics of
203 the DKD and non-DKD groups were similar. Median knee extensor strength was 1.7 Nm/kg (IQR,
204 1.5–2.0) in the DKD group and 2.3 Nm/kg (IQR, 1.2–2.8) in the non-DKD group, without significant
205 differences. Similarly, the mean (SD) SMI showed no significant difference between the DKD (7.5 kg/m²,
206 1.2) and non-DKD groups (7.7 kg/m², 1.2) (Table 1).

207 **Fatigability**

208 The mean (SD) Δ MVCC velocity for all participants was 35.9% (17.0), and the mean Δ MVIC torque was
209 26.7% (15.6). The mean Δ MVCC velocity of the DKD group was 39.8% (17.4), and that of the non-DKD
210 group was 29.5% (14.6); the DKD group had a significantly higher Δ MVCC velocity (Table 1, Fig 3).

211

212 **Fig 3** Differences in fatigability between DKD and non-DKD groups

213 This showed the MVCC velocity and MVIC torque during the baseline to dynamic fatiguing task.
214 Δ MVCC velocity at t3 and Δ MVIC torque at v3 indicated fatigability in this study. *MVCC* maximal
215 voluntary concentric contractions, *MVIC* maximal voluntary isometric contractions, *DKD* diabetic kidney
216 disease.

217

218 **Relationship between the presence of kidney disease and** 219 **fatigability**

220 The results of the regression analysis assessing the effect of kidney disease on fatigability were: After

221 adjusting for age, sex, knee extensor strength, and SMI, Δ MVCC velocity was significantly higher in the
222 DKD group compared with the non-DKD group ($F=4.235$, $p<0.05$). After adjusting for similar variables,
223 Δ MVIC torque was significantly higher in the DKD group compared with the non-DKD group ($F=4.853$,
224 $p<0.05$) (Table 2).

225

226 **Table 2 Fatigability comparison with and without DKD**

	DKD group	Non-DKD group	F	p
	n = 31	n = 19		
	Mean (SD)	Mean (SD)		
Δ MVCC velocity	39.8 (17.4)	29.5 (14.6)	4.235	0.046 [#]
Δ MVIC torque	29.8 (14.3)	21.5 (16.5)	4.853	0.033 [#]

227 Analysis of covariance was performed to compare fatigability between the two groups after adjusting for
228 age, sex, knee extensor strength, and skeletal muscle index.

229 *DKD* diabetic kidney disease, *MVCC* maximal voluntary concentric contractions, *MVIC* maximal
230 voluntary isometric contractions, *SD* standard deviation.

231 [#] $p < 0.05$

232

233 **Physical activity**

234 Of all the participants, 9 (18%) had low physical activity, 26 (52%) had moderate physical activity, and
235 15 (30%) had high physical activity. All 9 patients with low physical activity were in the DKD group, and
236 the DKD group had a significantly higher percentage of low physical activity than did the non-DKD
237 group (29% vs. 0%, $p<0.05$). The percentages of moderate and high physical activities did not differ
238 significantly between the DKD and non-DKD groups (Table 1).

239 **Relationship between fatigability and physical activity**

240 The results of ordinal logistic regression analysis adjusted for age, sex, knee extensor strength, and SMI
241 for all participants and the DKD and non-DKD groups were: In all participants, both Δ MVCC velocity
242 and Δ MVIC torque were significantly associated with physical activity (odds ratio [OR], 0.952; 95%

243 confidence interval [CI]: 0.919–0.987, $p < 0.05$ /OR, 0.962; 95% CI: 0.926–0.998, $p < 0.05$, respectively). In
244 the DKD group, Δ MVCC velocity was significantly associated with physical activity (OR: 0.045, 95%
245 CI: 0.913–0.999, $p < 0.05$). However, in the non-DKD group, neither Δ MVCC velocity nor Δ MVIC torque
246 was associated with physical activity (Tables 3 and 4).
247
248

249 **Table 3 Relationship between physical activity and Δ MVCC velocity in all participants, DKD group, and non-DKD group**

		Physical activity					
		All		DKD group		Non-DKD group	
		OR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value
Sex	Female	1		1		1	
	Male	1.224 (0.271–5.529)	0.793	2.691 (0.321–22.511)	0.361	0.785 (0.027–22.692)	0.888
Age		1.041 (0.958–1.132)	0.340	1.008 (0.907–1.121)	0.878	1.213 (0.994–1.480)	0.057
Δ MVCC velocity		0.952 (0.919–0.987)	0.007 [#]	0.955 (0.913–0.999)	0.045 [#]	0.968 (0.881–1.063)	0.494
Knee extension strength		1.103 (0.493–2.467)	0.811	0.481 (0.107–2.155)	0.339	1.343 (0.315–5.720)	0.690
Skeletal muscle index		0.934 (0.503–1.735)	0.830	0.751 (0.350–1.611)	0.462	1.782 (0.433–7.323)	0.423

250 To determine the relationship between physical activity and Δ MVCC velocity, ordinal logistic regression analysis was performed considering sex, age, knee
 251 extension strength, and skeletal muscle index in all participants, DKD group, and non-DKD group.

252 *DKD* diabetic kidney disease, *OR* odds ratio, *CI* confidence interval, *MVCC* maximal voluntary concentric contractions.

253 [#]*p* < 0.05

254

255 **Table 4 Relationship between physical activity and Δ MVIC torque in all participants, DKD group, and non-DKD group**

		Physical activity					
		All		DKD group		Non-DKD group	
		OR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value	OR (95% CI)	<i>p</i> -Value

		OR (95% CI)	p-Value	OR (95% CI)	p-Value	OR (95% CI)	p-Value
Sex	Female	1		1		1	
	Male	1.280 (0.288–5.686)	0.746	2.291 (0.285–18.430)	0.436	1.251 (0.042–37.003)	0.897
Age		1.031 (0.951–1.120)	0.451	0.999 (0.899–1.108)	0.978	1.229 (1.000–1.510)	0.050
Δ MVIC torque		0.962 (0.926–0.998)	0.041 [#]	0.952 (0.903–1.005)	0.073	1.016 (0.938–1.100)	0.701
Knee extension strength		1.281 (0.567–2.895)	0.551	0.777 (0.182–3.320)	0.734	0.986 (0.192–5.058)	0.987
Skeletal muscle index		0.884 (0.478–1.636)	0.695	0.662 (0.302–1.449)	0.302	1.510 (0.361–6.309)	0.572

256 To determine the relationship between physical activity and Δ MVIC torque, ordinal logistic regression analysis was performed considering sex, age, knee extension
 257 strength, and skeletal muscle index in all participants, DKD group, and non-DKD group.

258 *DKD* diabetic kidney disease, *OR* odds ratio, *CI* confidence interval, *MVIC* maximal voluntary isometric contractions.

259 [#] $p < 0.05$

260 **Discussion**

261 Fatigability was greater among patients with T2DM combined with DKD compared with those with
262 T2DM providing evidence that DKD is associated with greater fatigability among patients with T2DM.
263 Furthermore, fatigability may be related to the amount of physical activity required by patients with DKD.
264 Facilitating increased physical activity is crucial for individuals with DM, contributing to glycemic
265 control, preventing diabetic complications, and reducing the incidence of cardiovascular disease and
266 mortality [22,23]. A novel aspect of our study is that the focus on fatigability was increased by DKD
267 complications, suggesting that this increased fatigability may be associated with decreased physical
268 activity. Unlike chronic fatigue, fatigability can be modified with exercise therapy [24]. Therefore, this
269 study is clinically significant because it may identify a therapeutic target to increase physical activity. In a
270 previous study reporting fatigability in healthy older adults averaging approximately 70 years of age,
271 Δ MVCC velocity (male/female) was approximately 24.7%/23.1%, and Δ MVIC torque (male/female) was
272 approximately 23.2%/17.1% [16]. However, in this study involving patients aged 40–65 years, Δ MVCC
273 velocity was 29.5% and 39.8% in patients with non-DKD and DKD, respectively, whereas Δ MVIC torque
274 was 21.5% and 29.8% in patients with non-DKD and DKD, respectively. In other words, even in patients
275 with DM, fatigability rises to a level comparable to that in healthy elderly individuals. Furthermore, when
276 combined with DKD and diabetes, fatigability rises by more than 1.5 times that of healthy elderly
277 individuals, indicating its potential as a significant factor inhibiting an increase in physical activity.

278 **Mechanism of fatigability and involvement of DKD** 279 **complications in fatigability**

280 The following biological mechanisms are considered responsible for increased fatigability, including
281 activation of the motor cortex, descending motor neurons, spinal activation of motor neurons,
282 neuromuscular junction transmission, muscle perfusion (blood flow), muscle fiber excitation-contraction,
283 and energy metabolism (adenosine triphosphate regulation), and impairment of this process increases
284 fatigability [25]. A study comparing the fatigability of healthy adults and T2DM reported increased
285 fatigability in T2DM due to muscle contractile properties [26]. Substitution of the general process
286 suggests that excitation-contraction in muscle fibers is impaired. Besides this mechanism, increased

287 oxidative stress, skeletal muscle abnormalities due to CKD complications, and impaired microcirculation
288 due to decreased nitric oxide production may be factors that further increase fatigability in the DKD
289 group. Microcirculatory disturbances due to CKD complications reduce the rate of oxygen uptake into
290 tissues and impair oxygen delivery to mitochondria in muscle tissue [27,28]. Impaired oxygen delivery to
291 muscle tissue reduces adenosine triphosphate utilization efficiency and decreases calcium ion sensitivity
292 in myofibrils and calcium ion release capacity in the sarcoplasmic reticulum [11]. This phenomenon
293 occurs even in patients with mild renal impairment [29]. Furthermore, trace albuminuria is associated
294 with endothelial dysfunction, sarcopenia, and muscle strength [30-32], suggesting that peripheral tissue
295 abnormalities may also affect fatigability in early-stage patients, such as our participants. In other words,
296 the complications of DKD contribute to the process of increased fatigability in T2DM and enhance
297 fatigability by inducing biological changes in peripheral tissues due to the complications of CKD.

298 **Relationship between fatigability and physical activity**

299 Studies on healthy adults have reported a relationship between fatigability and physical activity [16,33].
300 However, the association remains unknown in the T2DM and DKD. The brain activity that occurs during
301 the preparatory phase of physical activity (motor-related cortical potential) is associated with the
302 perception of effort [34]. Moreover, greater muscle fatigability increases motor-related cortical potential
303 [35]. In other words, patients with increased fatigability have greater perceived effort during physical
304 activity. Increases in perceived effort decrease willingness to initiate physical activity [36]. Additionally,
305 patients with increased fatigability require more effort for cognitive processing because of reduced
306 oxygen supply to the brain due to excessive muscle hypermetabolism during physical activity [36]. Mild
307 renal impairment contributes to this process because of poor oxygen supply to the brain during activity
308 [37]. Thus, increased fatigability may be a barrier to the initiation and continuation of physical activity,
309 which may be further increased by the complications of DKD.

310 **Limitations**

311 This study has some limitations. First, the sample size was small owing to the single-center nature of the
312 study, and the fact that it was conducted with a limited number of subjects to account for age effects
313 reduced the generalizability and external validity. Second, the IPAQ-SF relies on subjective self-reporting,

314 which can be affected by respondents' perceptions and memory biases, potentially leading to inaccuracies,
315 particularly in individuals with fluctuating activity levels or vague recall of specific activities. Third, we
316 did not consider the impact of diabetic neuropathy (DN) as a factor related to fatigue. Currently, the gold
317 standard for DN is nerve conduction testing, which was not performed in this study. However, knee
318 extension strength and skeletal muscle mass were adjusted for as confounding factors in this study.
319 Muscle strength has been reported to be associated with the presence and severity of DN, although not
320 with albuminuria or retinopathy itself [38]. Moreover, patients with DN have been reported to have a
321 greater annual loss of muscle mass in the lower extremities than patients without DN, confirming the
322 association between DN and skeletal muscle mass [39]. Therefore, in this study, the effect of DN on
323 fatigability was minimal. Finally, the possibility that the severity and duration of DM itself are factors
324 contributing to increased fatigability was not taken into account. DM progression is associated with DKD
325 complications and increased fatigability. However, adjusting for this adaptive confounding factor was not
326 possible due to the lack of standardization in the severity assessment of T2DM, and the clinical
327 assessment of DM duration is challenging.

328

329 **Conclusions**

330 This study showed that complications of DKD in patients with T2DM increased activity-induced
331 fatigability. The findings also suggested a potential correlation between fatigability and the level of
332 physical activity, with a similar trend observed specifically among patients with DKD. These results aim
333 to shed light on factors associated with physical activity levels in patients with DKD and contribute to the
334 development of tailored physical activity and exercise programs based on patient characteristics. In the
335 future, conducting longitudinal studies to verify the effect of reducing fatigue on increasing physical
336 activity is crucial.

337

338 **Acknowledgments:** The authors thank the patients at the Hamamatsu University

339 Hospital who participated in this study. The authors would like to thank the staff and nurses for their
340 excellent patient care. We would like to thank Editage (www.editage.com) for the English language

341 editing.

342

343 **References**

344 1. Izzo A, Massimino E, Riccardi G, Della Pepa G. A Narrative Review on Sarcopenia in Type 2 Diabetes

345 Mellitus: Prevalence and Associated Factors. *Nutrients*. 2021; 13 (1):183. doi:10.3390/nu13010183

346 2. IJzerman TH, Schaper NC, Melai T, Meijer K, Willems PJ, Savelberg HH. Lower extremity muscle

347 strength is reduced in people with type 2 diabetes, with and without polyneuropathy, and is associated

348 with impaired mobility and reduced quality of life. *Diabetes Res Clin Pract*. 2012;95 (3):345-351.

349 doi:10.1016/j.diabres.2011.10.026

350 3. Nomura T, Ishiguro T, Ohira M, Ikeda Y. Regular exercise behavior is related to lower extremity

351 muscle strength in patients with type 2 diabetes: Data from the Multicenter Survey of the Isometric Lower

352 Extremity Strength in Type 2 Diabetes study. *J Diabetes Invest*. 2018; 9 (2):426-429.

353 doi:10.1111/jdi.12703

354 4. Senefeld J, Magill SB, Harkins A, Harmer AR, Hunter SK. Mechanisms for the increased fatigability

355 of the lower limb in people with type 2 diabetes. *J Appl Physiol (1985)*. 2018;125 (2):553-566.

356 doi:10.1152/jappphysiol.00160.2018

357 5. Enoka RM, Duchateau J. Translating Fatigue to Human Performance. *Med Sci Sports Exerc*. 2016; 48

358 (11):2228-2238. doi:10.1249/MSS.0000000000000929

359 6. Penner IK, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. *Nat Rev Neurol*.

360 2017;13 (11):662-675. doi:10.1038/nrneurol.2017.117

361 7. Gresham G, Dy SM, Zipunnikov V, Browner IS, Studenski SA, Simonsick EM, Ferrucci L, et al.

362 Fatigability and endurance performance in cancer survivors: Analyses from the Baltimore Longitudinal

363 Study of Aging. *Cancer*. 2018; 124 (6):1279-1287. doi:10.1002/cncr.31238

364 8. Silva-Migueis H, Martinez-Jimenez EM, Casado-Hernandez I, Dias A, Monteiro AJ, Martins RB, et al.

365 Influence of an Upper Limb Isometric Task in Perceived and Performance Fatigability of Elderly

366 Subjects: A Quasi-Experimental Study. *Biology (Basel)*. 2022; 11 (8):1175.


367 doi:10.3390/biology11081175

- 368 9. Senefeld JW, Limberg JK, Lukaszewicz KM, Hunter SK. Exercise-induced hyperemia is associated
369 with knee extensor fatigability in adults with type 2 diabetes. *J Appl Physiol* (1985). 2019; 126
370 (3):658-667. doi:10.1152/jappphysiol.00854.2018
- 371 10. Senefeld JW, Harmer AR, Hunter SK. Greater Lower Limb Fatigability in People with Prediabetes
372 than Controls. *Med Sci Sports Exerc*. 2020a; 52 (5):1176-1186. doi:10.1249/MSS.0000000000002238
- 373 11. Gollie JM, Patel SS, Harris-Love MO, Cohen SD, Blackman MR. Fatigability and the Role of
374 Neuromuscular Impairments in Chronic Kidney Disease. *Am J Nephrol*. 2022; 53 (4):253-263.
375 doi:10.1159/000523714
- 376 12. Zhou Y, Hellberg M, Svensson P, Hoglund P, Clyne N. Sarcopenia and relationships between muscle
377 mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease
378 stages 3-5. *Nephrol Dial Transplant*. 2018; 33 (2):342-348. doi:10.1093/ndt/gfw466
- 379 13. Stauffer ME, Fan T. Prevalence of Anemia in Chronic Kidney Disease in the United States. *Plos One*.
380 2014; 9 (1):e84943. doi:10.1371/journal.pone.0084943
- 381 13. Stauffer ME, Fan T. Prevalence of Anemia in Chronic Kidney Disease in the United States. *Plos One*.
382 2014; 9 (1):e84943. doi:10.1371/journal.pone.0084943
- 383 14. Seliger SL, Salimi S, Pierre V, Giffuni J, Katzell L, Parsa A. Microvascular endothelial dysfunction is
384 associated with albuminuria and CKD in older adults. *Bmc Nephrol*. 2016; 17(1):82.
385 doi:10.1186/s12882-016-0303-x
- 386 15. Gamboa JL, Billings FT 4th, Bojanowski MT, Gilliam LA, Yu C, Roshanravan B, et al.
387 Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. *Physiol Rep*.
388 2016; 4 (9) :e12780. doi:10.14814/phy2.12780
- 389 16. Senefeld J, Yoon T, Hunter SK. Age differences in dynamic fatigability and variability of arm and leg
390 muscles: Associations with physical function. *Exp Gerontol*. 2017; 87 (Pt A):74-83.
391 doi:10.1016/j.exger.2016.10.008
- 392 17. IPAQ International Physical Activity Questionnaire. 2020 [cited 2024 April 14]. Available from:
393 <https://sites.google.com/site/theipaq/>.
- 394 18. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised Equations for Estimated
395 GFR From Serum Creatinine in Japan. *Am J Kidney Dis*. 2009; 53 (6):982-992.
396 doi:10.1053/j.ajkd.2008.12.034

- 397 19. Roshanravan B, Gamboa J, Wilund K. Exercise and CKD: Skeletal Muscle Dysfunction and Practical
398 Application of Exercise to Prevent and Treat Physical Impairments in CKD. *Am J Kidney Dis.* 2017; 69
399 (6):837-852. doi:10.1053/j.ajkd.2017.01.051
- 400 20. Sundberg CW, Kuplic A, Hassanlouei H, Hunter SK. Mechanisms for the age-related increase in
401 fatigability of the knee extensors in old and very old adults. *J Appl Physiol* (1985). 2018; 125
402 (1):146-158. doi:10.1152/jappphysiol.01141.2017
- 403 21. Senefeld J, Yoon T, Bement MH, Hunter SK. Fatigue and recovery from dynamic contractions in men
404 and women differ for arm and leg muscles. *Muscle Nerve.* 2013; 48 (3):436-439. doi:10.1002/mus.23836
- 405 22. Rietz M, Lehr A, Mino E, Lang A, Szczerba E, Schiemann T, et al. Physical Activity and Risk of
406 Major Diabetes-Related Complications in Individuals With Diabetes: A Systematic Review and
407 Meta-Analysis of Observational Studies. *Diabetes Care.* 2022; 45 (12):3101-3111.
408 doi:10.2337/dc22-0886
- 409 23. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical
410 Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. *Diabetes*
411 *Care.* 2016; 39 (11):2065-2079. doi:10.2337/dc16-1728
- 412 24. Abdelbasset WK, Abdelhalim NM. Assessing the effects of 6 weeks of intermittent aerobic exercise
413 on aerobic capacity, muscle fatigability, and quality of life in diabetic burned patients: Randomized
414 control study. *Burns.* 2020; 46 (5):1193-1200. doi:10.1016/j.burns.2019.12.013
- 415 25. Hunter SK. Performance Fatigability: Mechanisms and Task Specificity. *Cold Spring Harb Perspect*
416 *Med.* 2018; 8 (7):a029728. doi:10.1101/cshperspect.a029728
- 417 26. Senefeld JW, Keenan KG, Ryan KS, D'Astice SE, Negro F, Hunter SK. Greater fatigability and motor
418 unit discharge variability in human type 2 diabetes. *Physiol Rep.* 2020b; 8 (13):e14503.
419 doi:10.14814/phy2.14503
- 420 27. Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS. Oxidant Mechanisms in Renal Injury and Disease.
421 *Antioxid Redox Signal.* 2016; 25 (3):119-146. doi:10.1089/ars.2016.6665
- 422 28. Prommer HU, Maurer J, von Websky K, Freise C, Sommer K, Nasser H, et al. Chronic kidney disease
423 induces a systemic microangiopathy, tissue hypoxia and dysfunctional angiogenesis. *Sci Rep.* 2018; 8
424 (1):5317. doi:10.1038/s41598-018-23663-1

- 425 29. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal
426 function is associated with markers of endothelial dysfunction and increased inflammatory activity.
427 *Nephrol Dial Transplant*. 2003; 18 (5):892-898. doi:10.1093/ndt/gfg080
- 428 30. Kataoka H, Miyatake N, Kitayama N, Murao S, Tanaka S. Decrease in toe pinch force in male type 2
429 diabetic patients with diabetic nephropathy. *Clin Exp Nephrol*. 2018; 22 (3):647-652.
430 doi:10.1007/s10157-017-1507-5
- 431 31. Chang CJ, Lin CH, Hsieh HM, Lo WY, Lai YH, Peng LN, et al. Risk of sarcopenia among older
432 persons with Type 2 diabetes mellitus with different status of albuminuria: A dose-responsive association.
433 *Arch Gerontol Geriatr*. 2021; 95:104338. doi:10.1016/j.archger.2021.104338
- 434 32. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is
435 associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and
436 with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction--the
437 Hoorn Study. *Kidney Int Suppl*. 2004; (92):S42-44. doi:10.1111/j.1523-1755.2004.09211.x
- 438 33. Buchowski MS, Simmons SF, Whitaker LE, Powers J, Beuscher L, Choi L, et al. Fatigability as a
439 function of physical activity energy expenditure in older adults. *Age*. 2013; 35 (1):179-187.
440 doi:10.1007/s11357-011-9338-x
- 441 34. de Morree HM, Klein C, Marcora SM. Perception of effort reflects central motor command during
442 movement execution. *Psychophysiology*. 2012; 49 (9):1242-1253. doi:10.1111/j.1469-8986.2012.01399.x
- 443 35. Berchicci M, Menotti F, Macaluso A, Di Russo F. The neurophysiology of central and peripheral
444 fatigue during sub-maximal lower limb isometric contractions. *Front Hum Neurosci*. 2013; 7:135.
445 doi:10.3389/fnhum.2013.00135
- 446 36. Ament W, Verkerke GJ. Exercise and fatigue. *Sports Med*. 2009; 39 (5):389-422.
447 doi:10.2165/00007256-200939050-00005
- 448 37. Theodorakopoulou MP, Dipla K, Zafeiridis A, Faitatzidou D, Koutlas A, Doumas M, et al. Cerebral
449 oxygenation during exercise deteriorates with advancing chronic kidney disease. *Nephrol Dial Transplant*.
450 2023; 38 (10):2379-2388. doi:10.1093/ndt/gfad076
- 451 38. Andersen H, Poulsen PL, Mogensen CE, Jakobsen J. Isokinetic muscle strength in long-term IDDM
452 patients in relation to diabetic complications. *Diabetes*. 1996; 45 (4):440-445. doi:10.2337/diab.45.4.440

453 39. Andreassen CS, Jakobsen J, Ringgaard S, Ejlskjær N, Andersen H. Accelerated atrophy of lower leg
454 and foot muscles--a follow-up study of long-term diabetic polyneuropathy using magnetic resonance
455 imaging (MRI). *Diabetologia*. 2009; 52 (6):1182-1191. doi:10.1007/s00125-009-1320-0
456



Patients with type 2 diabetes seen as outpatients
between April 2020 and March 2023 who met the
eligibility criteria (n=73)

Orthopedic disease (n=4)
Mental illness (n=6)
Respiratory disease (n=2)
Stroke (n=1)
Nonconsensual (n=3)
Other (n=7)

Included in the final analysis (n=50)

DKD group
(n = 31)

non-DKD group
(n = 19)

